Project Grant R01CA300233
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $731,503 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026 through May 31, 2031. This grant funds a randomized controlled trial (RCT) evaluating Brief Behavioral Activation (BBA) as a telehealth-delivered intervention for treating depression in older adult cancer survivors (OACS) aged 65 and older. The research addresses a...
- Federal Project Grant Award Summary The National Cancer Institute awarded $292,028 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, and concluding July 31, 2030. This five-year Project Grant supports research investigating genome instability associated with focal oncogene amplification (OA) and the development of therapeutic strategies to address treatment-resistant cancers. The research deliverables include...
- Federal Project Grant Award Summary The National Cancer Institute awarded $457,252 to Memorial Sloan Kettering Cancer Center's Sloan-Kettering Institute for Cancer Research on June 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test RECONJOINT, a web-based shared decision-making tool for breast reconstruction surgery. The project addresses a critical gap in patient-centered care, as approximately 40% of women undergoing breast reconstruction...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $546,842 (awarded July 1, 2026; completion June 30, 2031) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct research on germline determinants of tumor development and treatment response. The project will deliver a meta-analysis framework and functional validation studies identifying how inherited germline...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary Award Overview The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded $807,644 to Sloan-Kettering Institute for Cancer Research effective August 13, 2025, through July 31, 2030. This Project Grant funds the development and pilot testing of DESCANSO (Depression, Fatigue, and Sleep/Rest), a culturally adapted cognitive behavioral therapy (CBT) intervention designed to address the co-occurring symptom...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $366,662 to the Sloan-Kettering Institute for Cancer Research, effective July 1, 2026 through June 30, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393). This grant funds the development of novel statistical methodologies for conducting mediation analysis using epidemiologic data from multiple incomplete data sources. The research addresses a critical gap in current...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute For Cancer Research a $452,540 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award supports research to develop and validate electronic nose (e-nose) technology utilizing volatile organic compounds (VOCs) in patient exhalates to predict and assess pathologic response to neoadjuvant therapy in patients with...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $730,398 to Sloan-Kettering Institute for Cancer Research through the Cancer Treatment Research program (CFDA 93.395) on September 1, 2025, for a five-year project period concluding August 31, 2030. This Project Grant supports research and development activities designed to advance novel treatment approaches for rectal cancer, with emphasis on organ preservation strategies that minimize patient morbidity. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $444,590 under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with a completion date of May 31, 2028. This grant supports a comprehensive evaluation of genetic and epigenetic determinants that influence treatment response in patients with advanced myeloproliferative neoplasms (MPNs)—specifically accelerated-phase and blast-phase...
The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $745,458 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period July 1, 2026 through June 30, 2031. The award funds development and implementation of the PERSON Intervention, an innovative digital health solution designed to facilitate person-centered communication between oncology patients and clinicians. The intervention leverages patient portals to systematically elicit and deliver essential patient-reported information regarding communication preferences, illness and treatment understanding, and personal health values and priorities. This automated, scalable system comprises three integrated components: a 14-item PERSON questionnaire administered through the patient portal, delivery of patient responses to the oncology care team, and clinical decision support tools enabling providers to document and discuss responses within the electronic health record. The project employs a hybrid Type 2 study design to assess the effectiveness and implementation feasibility of the PERSON Intervention in outpatient oncology settings. By repeating the assessment process at four-month intervals, the intervention accommodates evolving patient needs and priorities while supporting shared decision-making and individualized care planning—particularly for patients with advanced disease. This research addresses a critical implementation challenge in high-volume oncology clinics: delivering consistent, efficient, and effective person-centered communication that ensures patients both understand their illness and feel recognized as individuals with distinct values and concerns.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $745.5k | 6/30/26 |